Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tingting Zhao
Institution:
Arcus Biosciences (United States)
Observed institution:
Arcus Biosciences (United States)
ORCID:
0009-0002-7725-5696
Observed ORCID:
0009-0002-7725-5696
OpenAlex ID:
A5139837126
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
·
Clinical Cancer Research
·
10
PDF
Data from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Figure S2 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Figure S1 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Table S2 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Table S3 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Table S1 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Supplementary Figure S3 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026
·
Michael Cecchini
, Sae-Won Han
, et al.
Abstract B024: The clinical benefit from treatment of advanced MSS mCRC with the adenosine 2a/2b antagonist etrumadenant is associated with adenosine-mediated T-cell exclusion and enhancement of the effectiveness of immunotherapy
2026
·
Jiyun Kim
, Emily Brown
, et al.
·
Cancer Immunology Research
Show more works
View as search
Works count:
9
Citation count:
10
H-index:
1
I10-index:
1
Year
Topic
Type